PER 0.00% 10.5¢ percheron therapeutics limited

Ann: ATL1103 Acromegaly Phase II Trial Results, page-91

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 13,417 Posts.
    lightbulb Created with Sketch. 1439
    12/8/14
    Laidlaw initiates coverage on Isis PHARMA with a Buy target of $52
    Analyst Yale Jen said "Supported by clinically validated Antisense Technologyies,multiple mid to late-stage clinical programs and corporate partnerships.
    Yes people Antisense compounds are validated.....be very excited $$$
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.